{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:37:31Z","timestamp":1780051051363,"version":"3.53.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["grant 2021JJ30927"],"award-info":[{"award-number":["grant 2021JJ30927"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["grant C202303066112"],"award-info":[{"award-number":["grant C202303066112"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["grant 81670804"],"award-info":[{"award-number":["grant 81670804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The diagnosis of fibrodysplasia ossificans progressiva is missed or delayed because of its insidious precursors, especially in uncharacteristic cases. Fibrodysplasia ossificans progressiva, which mostly displayed the mutation c.617G\u2009&gt;\u2009A, p.R206H, is characterized by congenital malformation of the great toe and progressive extra-skeletal ossification of ligaments, tendons and muscles. The mutation c.774G\u2009&gt;\u2009C, p.R258S (HGVS: NC_000002.11:g.158626896\u00a0C\u2009&gt;\u2009G) in activin A receptor type I is an infrequent etiology of fibrodysplasia ossificans progressiva and can present different clinical features. Awareness of these multiple clinical features will help endocrinologists in the early diagnosis of fibrodysplasia ossificans progressiva. We report a case of fibrodysplasia ossificans progressiva with the activin A receptor type I mutation c.774G\u2009&gt;\u2009C, p.R258S, which was diagnosed before its ossifying period.<\/jats:p>","DOI":"10.1186\/s13023-024-03363-y","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T12:03:13Z","timestamp":1727697793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Challenges in the diagnosis of fibrodysplasia ossificans progressiva with the ACVR1 mutation (c.774G\u2009&gt;\u2009C, p.R258S): a case report and review of literature"],"prefix":"10.1186","volume":"19","author":[{"given":"Siqi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2058-9815","authenticated-orcid":false,"given":"Ruchun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"1","key":"3363_CR1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Hsiao EC, Baujat G, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16(1):350. Published 2021 Aug 5.","journal-title":"Orphanet J Rare Dis"},{"key":"3363_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1750-1172-6-80","volume":"6","author":"RJ Pignolo","year":"2011","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80. Published 2011 Dec 1.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3363_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat G, Choquet R, Bou\u00e9e S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123. Published 2017 Jun 30.","journal-title":"Orphanet J Rare Dis"},{"key":"3363_CR4","doi-asserted-by":"crossref","unstructured":"Smilde BJ, Botman E, de Ruiter RD et al. Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [published correction appears in Orthop Res Rev. 2022;14:147\u2013148. doi: 10.2147\/ORR.S373122]. Orthop Res Rev. 2022;14:113\u2013120. Published 2022 Apr 20.","DOI":"10.2147\/ORR.S337491"},{"issue":"12","key":"3363_CR5","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","volume":"24","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Brown MA, et al. The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study. Genet Med. 2022;24(12):2422\u201333.","journal-title":"Genet Med"},{"issue":"1","key":"3363_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13023-019-1096-3","volume":"14","author":"RJ Pignolo","year":"2019","unstructured":"Pignolo RJ, Baujat G, Brown MA, et al. Correction to: natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019;14(1):113. Published 2019 May 23.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3363_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jbmr.3304","volume":"33","author":"MR Convente","year":"2018","unstructured":"Convente MR, Chakkalakal SA, Yang E, et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1R206H mouse model of Fibrodysplasia ossificans Progressiva. J Bone Min Res. 2018;33(2):269\u201382.","journal-title":"J Bone Min Res"},{"issue":"11","key":"3363_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/cells8111366","volume":"8","author":"JA Valer","year":"2019","unstructured":"Valer JA, S\u00e1nchez-de-Diego C, Pimenta-Lopes C, et al. ACVR1 function in Health and Disease. Cells. 2019;8(11):1366. Published 2019 Oct 31.","journal-title":"Cells"},{"issue":"3","key":"3363_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1097-2765(01)00332-X","volume":"8","author":"M Huse","year":"2001","unstructured":"Huse M, Muir TW, Xu L, et al. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell. 2001;8(3):671\u201382.","journal-title":"Mol Cell"},{"issue":"3","key":"3363_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0092-8674(00)80555-3","volume":"96","author":"M Huse","year":"1999","unstructured":"Huse M, Chen YG, Massagu\u00e9 J, et al. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell. 1999;96(3):425\u201336.","journal-title":"Cell"},{"key":"3363_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cytogfr.2015.11.005","volume":"27","author":"D Yadin","year":"2016","unstructured":"Yadin D, Knaus P, Mueller TD. Structural insights into BMP receptors: specificity, activation and inhibition. Cytokine Growth Factor Rev. 2016;27:13\u201334.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"3363_CR12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","volume":"33","author":"A Bataller","year":"2019","unstructured":"Bataller A, Montalban-Bravo G, Soltysiak KA, et al. The role of TGF-\u03b2 in hematopoiesis and myeloid disorders. Leukemia. 2019;33(5):1076\u201389.","journal-title":"Leukemia"},{"issue":"2","key":"3363_CR13","doi-asserted-by":"publisher","first-page":"a022129","DOI":"10.1101\/cshperspect.a022129","volume":"9","author":"YE Zhang","year":"2017","unstructured":"Zhang YE. Non-smad Signaling pathways of the TGF-\u03b2 family. Cold Spring Harb Perspect Biol. 2017;9(2):a022129. Published 2017 Feb 1.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"3363_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/biomedicines12040779","volume":"12","author":"L Mejias Rivera","year":"2024","unstructured":"Mejias Rivera L, Shore EM, Mourkioti F. Cellular and Molecular mechanisms of Heterotopic Ossification in Fibrodysplasia ossificans Progressiva. Biomedicines. 2024;12(4):779. Published 2024 Apr 2.","journal-title":"Biomedicines"},{"key":"3363_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cca.2022.06.005","volume":"532","author":"R Zhang","year":"2022","unstructured":"Zhang R, Hao Y, Xu Y, et al. Whole exome sequencing identified a homozygous novel mutation in SUOX gene causes extremely rare autosomal recessive isolated sulfite oxidase deficiency. Clin Chim Acta. 2022;532:115\u201322.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"3363_CR16","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/jcmm.14768","volume":"24","author":"P Han","year":"2020","unstructured":"Han P, Wei G, Cai K, et al. Identification and functional characterization of mutations in LPL gene causing severe hypertriglyceridaemia and acute pancreatitis. J Cell Mol Med. 2020;24(2):1286\u201399.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"3363_CR17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/jcmm.14887","volume":"24","author":"R Zhang","year":"2020","unstructured":"Zhang R, Chen S, Han P, et al. Whole exome sequencing identified a homozygous novel variant in CEP290 gene causes Meckel syndrome. J Cell Mol Med. 2020;24(2):1906\u201316.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"3363_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/jcmm.13979","volume":"23","author":"Y Dai","year":"2019","unstructured":"Dai Y, Liang S, Dong X, et al. Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy. J Cell Mol Med. 2019;23(2):811\u20138.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"3363_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"9","key":"3363_CR20","doi-asserted-by":"publisher","first-page":"dmm046441","DOI":"10.1242\/dmm.046441","volume":"13","author":"AK Kaliya-Perumal","year":"2020","unstructured":"Kaliya-Perumal AK, Carney TJ, Ingham PW. Fibrodysplasia ossificans progressiva: current concepts from bench to bedside. Dis Model Mech. 2020;13(9):dmm046441. Published 2020 Sep 21.","journal-title":"Dis Model Mech"},{"key":"3363_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bone.2017.08.032","volume":"109","author":"N Mantick","year":"2018","unstructured":"Mantick N, Bachman E, Baujat G, et al. The FOP connection Registry: design of an international patient-sponsored registry for Fibrodysplasia ossificans Progressiva. Bone. 2018;109:285\u201390.","journal-title":"Bone"},{"issue":"3","key":"3363_CR22","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2106\/JBJS.I.00705","volume":"92","author":"FS Kaplan","year":"2010","unstructured":"Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686\u201391.","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"3363_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13023-022-02224-w","volume":"17","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Bedford-Gay C, Cali A, et al. Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective. Orphanet J Rare Dis. 2022;17(1):168. Published 2022 Apr 18.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3363_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137.","journal-title":"Nat Genet"},{"key":"3363_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bone.2017.06.011","volume":"109","author":"DM Alessi Wolken","year":"2018","unstructured":"Alessi Wolken DM, Idone V, Hatsell SJ, et al. The obligatory role of activin A in the formation of heterotopic bone in Fibrodysplasia ossificans Progressiva. Bone. 2018;109:210\u20137.","journal-title":"Bone"},{"key":"3363_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bone.2017.11.014","volume":"109","author":"H Wang","year":"2018","unstructured":"Wang H, Shore EM, Pignolo RJ, et al. Activin a amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Bone. 2018;109:218\u201324.","journal-title":"Bone"},{"key":"3363_CR27","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, B\u00e4chinger HP, et al. Osteogenesis Imperfecta. Nat Rev Dis Primers. 2017;3:17052. Published 2017 Aug 18.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"3363_CR28","doi-asserted-by":"publisher","first-page":"e10174","DOI":"10.1002\/jbm4.10174","volume":"3","author":"JT Tauer","year":"2019","unstructured":"Tauer JT, Robinson ME, Rauch F. Osteogenesis Imperfecta: New perspectives from Clinical and Translational Research. JBMR Plus. 2019;3(8):e10174. Published 2019 Feb 20.","journal-title":"JBMR Plus"},{"key":"3363_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/TACG.S197205","volume":"12","author":"R Nenna","year":"2019","unstructured":"Nenna R, Turchetti A, Mastrogiorgio G, et al. COL2A1 gene mutations: mechanisms of Spondyloepiphyseal Dysplasia Congenita. Appl Clin Genet. 2019;12:235\u20138. Published 2019 Dec 4.","journal-title":"Appl Clin Genet"},{"issue":"19","key":"3363_CR30","doi-asserted-by":"publisher","first-page":"11168","DOI":"10.3390\/ijms231911168","volume":"23","author":"G De Ponti","year":"2022","unstructured":"De Ponti G, Donsante S, Frigeni M, et al. MPSI manifestations and Treatment Outcome: skeletal focus. Int J Mol Sci. 2022;23(19):11168. Published 2022 Sep 22.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"3363_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ymgme.2018.04.011","volume":"125","author":"SA Khan","year":"2018","unstructured":"Khan SA, Mason RW, Giugliani R, et al. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. Mol Genet Metab. 2018;125(1\u20132):44\u201352.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3363_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/ejhg.2008.178","volume":"17","author":"R Bocciardi","year":"2009","unstructured":"Bocciardi R, Bordo D, Di Duca M, et al. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur J Hum Genet. 2009;17(3):311\u20138.","journal-title":"Eur J Hum Genet"},{"key":"3363_CR33","doi-asserted-by":"publisher","first-page":"15055","DOI":"10.1038\/hgv.2015.55","volume":"2","author":"Y Nakahara","year":"2015","unstructured":"Nakahara Y, Suzuki R, Katagiri T, et al. Phenotypic differences of patients with fibrodysplasia ossificans progressive due to p.Arg258Ser variants of ACVR1. Hum Genome Var. 2015;2:15055. Published 2015 Dec 10.","journal-title":"Hum Genome Var"},{"issue":"255","key":"3363_CR34","doi-asserted-by":"publisher","first-page":"255ra132","DOI":"10.1126\/scitranslmed.3008810","volume":"6","author":"JR Peterson","year":"2014","unstructured":"Peterson JR, De La Rosa S, Eboda O, et al. Treatment of heterotopic ossification through remote ATP hydrolysis. Sci Transl Med. 2014;6(255):255ra132.","journal-title":"Sci Transl Med"},{"issue":"3","key":"3363_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/CORR.0000000000000594","volume":"477","author":"AD Robertson","year":"2019","unstructured":"Robertson AD, Chiaramonti AM, Nguyen TP, et al. Failure of Indomethacin and Radiation to Prevent Blast-induced heterotopic ossification in a Sprague-Dawley Rat Model. Clin Orthop Relat Res. 2019;477(3):644\u201354.","journal-title":"Clin Orthop Relat Res"},{"key":"3363_CR36","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jpeds.2021.02.037","volume":"232S","author":"P Kannu","year":"2021","unstructured":"Kannu P, Levy CE. Evolving management of Fibrodysplasia ossificans Progressiva. J Pediatr. 2021;232S:S9\u201315.","journal-title":"J Pediatr"},{"key":"3363_CR37","doi-asserted-by":"crossref","unstructured":"Haviv R, Zeitlin L, Moshe V et al. Long term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva. Rheumatology (Oxford). Published online May 11, 2024.","DOI":"10.1093\/rheumatology\/keae255"},{"key":"3363_CR38","doi-asserted-by":"publisher","first-page":"732728","DOI":"10.3389\/fendo.2021.732728","volume":"12","author":"RD de Ruiter","year":"2021","unstructured":"de Ruiter RD, Smilde BJ, Pals G, et al. Fibrodysplasia ossificans Progressiva: what have we achieved and where are we now? Follow-up to the 2015 Lorentz Workshop. Front Endocrinol (Lausanne). 2021;12:732728. Published 2021 Nov 10.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"3363_CR39","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/biomedicines9070736","volume":"9","author":"T Katagiri","year":"2021","unstructured":"Katagiri T, Tsukamoto S, Kuratani M. Accumulated knowledge of activin receptor-like kinase 2 (ALK2)\/Activin A receptor, type 1 (ACVR1) as a target for Human disorders. Biomedicines. 2021;9(7):736. Published 2021 Jun 26.","journal-title":"Biomedicines"},{"issue":"8","key":"3363_CR40","doi-asserted-by":"publisher","first-page":"e95042","DOI":"10.1172\/jci.insight.95042","volume":"6","author":"E Williams","year":"2021","unstructured":"Williams E, Bagarova J, Kerr G, et al. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 2021;6(8):e95042. Published 2021 Apr 22.","journal-title":"JCI Insight"},{"issue":"10","key":"3363_CR41","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41591-023-02561-8","volume":"29","author":"M Di Rocco","year":"2023","unstructured":"Di Rocco M, Forleo-Neto E, Pignolo RJ, et al. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2023;29(10):2615\u201324.","journal-title":"Nat Med"},{"issue":"2","key":"3363_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/biom14020147","volume":"14","author":"H Wang","year":"2024","unstructured":"Wang H, Kaplan FS, Pignolo RJ. The HIF-1\u03b1 and mTOR pathways amplify heterotopic ossification. Biomolecules. 2024;14(2):147. Published 2024 Jan 24.","journal-title":"Biomolecules"},{"issue":"1","key":"3363_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13023-020-01406-8","volume":"15","author":"H Maekawa","year":"2020","unstructured":"Maekawa H, Kawai S, Nishio M, et al. Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1. Orphanet J Rare Dis. 2020;15(1):122. Published 2020 May 24.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3363_CR44","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI93521","volume":"127","author":"K Hino","year":"2017","unstructured":"Hino K, Horigome K, Nishio M, et al. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest. 2017;127(9):3339\u201352.","journal-title":"J Clin Invest"},{"issue":"3","key":"3363_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jbmr.4762","volume":"38","author":"RJ Pignolo","year":"2023","unstructured":"Pignolo RJ, Hsiao EC, Al Mukaddam M, et al. Reduction of New Heterotopic ossification (HO) in the Open-Label, phase 3 MOVE trial of Palovarotene for Fibrodysplasia ossificans Progressiva (FOP). J Bone Min Res. 2023;38(3):381\u201394.","journal-title":"J Bone Min Res"},{"issue":"3","key":"3363_CR46","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/ijms24032299","volume":"24","author":"RD de Ruiter","year":"2023","unstructured":"de Ruiter RD, Wisse LE, Schoenmaker T, et al. TGF-Beta induces activin a production in dermal fibroblasts derived from patients with Fibrodysplasia ossificans Progressiva. Int J Mol Sci. 2023;24(3):2299. Published 2023 Jan 24.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3363_CR47","doi-asserted-by":"publisher","first-page":"e10567","DOI":"10.15252\/emmm.201910567","volume":"11","author":"JA Valer","year":"2019","unstructured":"Valer JA, S\u00e1nchez-de-Diego C, G\u00e1mez B, et al. Inhibition of phosphatidylinositol 3-kinase \u03b1 (PI3K\u03b1) prevents heterotopic ossification. EMBO Mol Med. 2019;11(9):e10567.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"3363_CR48","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1530\/EOR-23-0207","volume":"9","author":"B Lai","year":"2024","unstructured":"Lai B, Jiang H, Gao Y, et al. Research trends and hotspots of myositis ossificans: a bibliometric analysis from 1993 to 2022. EFORT Open Rev. 2024;9(7):589\u201399. Published 2024 Jul 1.","journal-title":"EFORT Open Rev"},{"issue":"6699","key":"3363_CR49","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1126\/science.adq7356","volume":"384","author":"M Leslie","year":"2024","unstructured":"Leslie M. Drug development blossoms for rare, fatal bone disease. Science. 2024;384(6699):943\u20134.","journal-title":"Science"},{"issue":"749","key":"3363_CR50","doi-asserted-by":"publisher","first-page":"eabp8334","DOI":"10.1126\/scitranslmed.abp8334","volume":"16","author":"AJ Davis","year":"2024","unstructured":"Davis AJ, Brooijmans N, Brubaker JD, et al. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. Sci Transl Med. 2024;16(749):eabp8334.","journal-title":"Sci Transl Med"},{"issue":"757","key":"3363_CR51","doi-asserted-by":"publisher","first-page":"eabn3486","DOI":"10.1126\/scitranslmed.abn3486","volume":"16","author":"K He","year":"2024","unstructured":"He K, Jiang H, Li W, et al. Primary cilia mediate skeletogenic BMP and hedgehog signaling in heterotopic ossification. Sci Transl Med. 2024;16(757):eabn3486.","journal-title":"Sci Transl Med"},{"issue":"4","key":"3363_CR52","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/biom14040485","volume":"14","author":"RJ Pignolo","year":"2024","unstructured":"Pignolo RJ, Kaplan FS, Wang H. Cell senescence in Heterotopic Ossification. Biomolecules. 2024;14(4):485. Published 2024 Apr 16.","journal-title":"Biomolecules"},{"issue":"3","key":"3363_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/biom14030357","volume":"14","author":"A Diolintzi","year":"2024","unstructured":"Diolintzi A, Pervin MS, Hsiao EC. Immunologic aspects in Fibrodysplasia ossificans Progressiva. Biomolecules. 2024;14(3):357. Published 2024 Mar 16.","journal-title":"Biomolecules"},{"issue":"3","key":"3363_CR54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/biom14030347","volume":"14","author":"Q Cong","year":"2024","unstructured":"Cong Q, Yang Y. Hedgehog signaling controls Chondrogenesis and ectopic bone formation via the Yap-Ihh Axis. Biomolecules. 2024;14(3):347. Published 2024 Mar 14.","journal-title":"Biomolecules"},{"issue":"4","key":"3363_CR55","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/jbmr\/zjae029","volume":"39","author":"V Lounev","year":"2024","unstructured":"Lounev V, Groppe JC, Brewer N, et al. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice. J Bone Min Res. 2024;39(4):382\u201398.","journal-title":"J Bone Min Res"},{"issue":"1","key":"3363_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12964-024-01533-w","volume":"22","author":"F Liu","year":"2024","unstructured":"Liu F, Zhao Y, Pei Y, et al. Role of the NF-kB signalling pathway in heterotopic ossification: biological and therapeutic significance. Cell Commun Signal. 2024;22(1):159. Published 2024 Mar 4.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"3363_CR57","doi-asserted-by":"publisher","first-page":"e202302219","DOI":"10.26508\/lsa.202302219","volume":"7","author":"L Sun","year":"2024","unstructured":"Sun L, Jin Y, Nishio M, et al. Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva. Life Sci Alliance. 2024;7(5):e202302219. Published 2024 Feb 16.","journal-title":"Life Sci Alliance"},{"issue":"9\u201310","key":"3363_CR58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/hum.2024.022","volume":"35","author":"C Lin","year":"2024","unstructured":"Lin C, Greenblatt MB, Gao G, et al. Development of AAV-Mediated Gene Therapy approaches to treat skeletal diseases. Hum Gene Ther. 2024;35(9\u201310):317\u201328.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"3363_CR59","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/biom14030349","volume":"14","author":"C Juan","year":"2024","unstructured":"Juan C, Bancroft AC, Choi JH, et al. Intersections of Fibrodysplasia ossificans Progressiva and traumatic heterotopic ossification. Biomolecules. 2024;14(3):349. Published 2024 Mar 14.","journal-title":"Biomolecules"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03363-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03363-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03363-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T23:03:12Z","timestamp":1727737392000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03363-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3363"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03363-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Written informed consent was obtained from the parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The parents have consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}